Company Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Sean Nolan |
Contact Details
Address: 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 United States | |
| Phone | 214 612 0000 |
| Website | tayshagtx.com |
Stock Details
| Ticker Symbol | TSHA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001806310 |
| CUSIP Number | 877619106 |
| ISIN Number | US8776191061 |
| Employer ID | 84-3199512 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sean P. Nolan | Chief Executive Officer and Chairman |
| Dr. Sukumar Nagendran M.D. | President, Head of Research and Development and Director |
| Kamran Alam CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Hayleigh Collins | Director of Corporate Communications and Investor Relations |
| Tracy M. Porter SPHR | Chief People Officer |
| Frederick Porter Ph.D. | Chief of Staff and Technical Operations Officer |
| Emily McGinnis M.P.H. | Chief Patient and External Affairs Officer and Endpoint & Outcome Development Lead |
| Sean McAuliffe | Chief Business Officer |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |